

Dr Henning Gädeke
c/o Dr Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

3 June 2026

**RE: Letter of endorsement in support of CUREMAL (101248948-2) under the
HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage call for proposal**

Dear Dr Gädeke,

In accordance with Council Regulation (EU) No. 2085/2021 of 19 November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, MMV Medicines for Malaria Venture (MMV), Route de Pré-Bois 20, Post Box 1826, CH-1215 Geneva 15, Switzerland, hereby submits an endorsement letter declaring cash and in-kind support to the **CUREMAL** (101248948-2) project submitted in response to the HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage call.

MMV, a partner in the CUREMAL consortium, is a Swiss not-for-profit foundation working through a Product Development Partnership model to deliver a portfolio of accessible medicines with the power to treat, prevent and eliminate malaria. Our work to deliver novel interventions against malaria is strongly aligned with GH EDCTP3's vision to reduce the burden of poverty-related infectious diseases in sub-Saharan Africa. By providing novel, effective, convenient, and scalable solutions, we support the acceleration of global progress towards malaria elimination, strengthen health systems, and contribute profoundly to global health security and social and economic development in LMICs. Reducing the global malaria disease burden contributes to the achievement of several Sustainable Development Goals (SDGs 3, 5 and 17). Our success is built on strong partnerships with pharmaceutical companies, academia and public health stakeholders across the world.

The focus of CUREMAL is to develop and evaluate a new non-artemisinin-based antimalarial therapy aimed at combating the growing problem of drug resistance in malaria treatment. By exploring alternative therapeutic options beyond the current artemisinin-based regimens, the project seeks to improve the effectiveness and sustainability of malaria control efforts. The research is designed to address the urgent need for innovative treatments that can overcome resistance and ensure better health outcomes for populations affected by malaria.

MMV will particularly contribute to the following aspects of the consortium's activities;

PK analysis, drug-drug interactions, modelling and adjustment of treatment (Study 1 and 2) under work package 3 'Clinical trials', task 3.9. MMV will also provide support in any other aspects of the project where its experience and capabilities can add value under work packages 1 Coordination and 2 Scientific project leadership. The total estimated person months for these activities are 5. with an estimated value of this in-kind contribution of € 98,899. Adding up 25% indirect cost (€ 24,725), in total MMV estimates its contribution at € 123,623.

If successful, the new regimen could replace artemisinin-based therapies as the first-line treatment for uncomplicated malaria, particularly benefiting vulnerable populations such as children and those in high-transmission regions. The project will also establish a robust genomic surveillance network for antimalarial resistance, build local research and laboratory capacity, and foster African scientific leadership. By improving treatment efficacy, reducing malaria morbidity and mortality, and strengthening resistance monitoring, CUREMAL is expected to contribute directly to achieving Sustainable Development Goal 3, support updates to national and international malaria treatment guidelines, and serve as a model for future infectious disease surveillance and control efforts. Projections suggest that, under high-resistance scenarios, the intervention could prevent millions of malaria cases and save tens of thousands of lives annually in SSA, while also reducing healthcare costs and supporting socio-economic development.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.

4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully
Martin Fitchet

Digitally signed by Nitro Software
Belgium NV - Nitro Sign Premium on
behalf of Martin Fitchet
Date: 01/06/2026 17:43:56

Dr Martin Fitchet M.D.
Chief Executive Officer